Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

PFE 32.14 -0.02 (-0.06%)
price chart
Pfizer Posts Strong Profits, Faces Strong Headwinds
Steps are being made in a positive direction, as Pfizer plans to spin off up to 20 percent of its animal health business in an initial public offering (IPO) this August.
Retailers sue Pfizer, charge generic Lipitor delay
The exterior of Pfizer in Groton, Conn. Pfizer Inc. Shares of Pfizer Inc. and Bristol-Myers Squibb Co. fell Monday, June 25, 2012, after federal regulators unexpectedly delayed for a second time a decision on whether to approve the companies' highly ...
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
PFE Breaking Out After Long Series of Corrections
Pfizer Inc. (NYSE:PFE) - This is the world's largest pharmaceutical company producing a wide range of drugs. In October 2009, it acquired Wyeth.
Pfizer's Lyrica does not hurt sperm in study
Pfizer Inc said a clinical study found its Lyrica nerve pain treatment did not affect sperm production in men taking the pill.
Top-line results in Pfizer's Lyrica long term safety study for ...  News-Medical.net
Hopes dim for Alzheimer's trials after Pfizer failure
Investor hopes for two experimental Alzheimer's treatments have grown even fainter after Pfizer Inc said its treatment failed in one of four big clinical trials.
Pfizer-Janssen Alzheimer's Treatment Misses Phase III Endpoints  Genetic Engineering News
Alzheimer's Drug Fails a Late-Stage Clinical Trial  TIME
Pfizer Wins Lyrica Patent Ruling
A U.S. judge has upheld the validity of patents covering Pfizer Inc.'s pain drug Lyrica, preserving market U.S. exclusivity for one of the company's best-selling drugs through 2018.
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for the exclusive ...
Another look at esreboxetine: 4th Rx alternative for fibromyalgia?
Pfizer announced that they were discontinuing phase 3 trials of esreboxetine after their review of existing phase 2 trial data indicated the drug was unlikely to “provide meaningful benefit to patients beyond” other fibromyalgia Rx therapies that were ...
CCP opens second phase review on Nestl�'s Pfizer acquisition
ISLAMABAD: The Competition Commission of Pakistan (CCP), in concluding the first phase review of the pre-merger application for acquisition of the nutrition business of Pfizer Inc by Nestl� SA, has ordered a second phase review. The preliminary ...